Search

Resumen Introduccion El hemangioma infantil (HI) es el tumor mas frecuente de la infancia. Es un tumor benigno de origen vascular, que afecta a la edad pediatrica exclusivamente. La mayoria sigue un curso clinico benigno y se resuelve sin necesidad de tratamiento, aunque con frecuencia origina lesiones residuales una vez resuelto. El objetivo de este estudio fue realizar un estudio descriptivo de los HI evaluados en un hospital terciario, evaluar la incidencia de lesiones residuales y predecir los factores relacionados con el desarrollo de las mismas. Material y metodos Se realizo un estudio observacional retrospectivo recogiendo los HI de los que se disponia de imagenes clinicas evaluados en el Servicio de Dermatologia del Hospital Clinico Universitario de Valencia, en el periodo comprendido entre enero de 2009 y diciembre de 2017. Resultados La forma clinica de presentacion mas frecuente fue: 74,6% de sexo femenino, 73,1% lesion unica, edad media de aparicion de 1,5 meses, 63,3% con componente superficial, 83,3% focales, 51,1% localizados en la cabeza o el cuello, 80% ≤3 cm. Un 51,5% de los pacientes recibio tratamiento con propranolol, desarrollando alguna reaccion adversa en un 17,6% de los casos, fundamentalmente terrores nocturnos. Conclusiones Un 69,2% de los HI desarrollaron secuelas esteticas al involucionar. La invasion de la dermis superficial por la tumoracion, una menor edad de inicio y la ausencia de una lesion precursora al nacimiento se relacionaron de forma estadisticamente significativa con un mayor riesgo de secuela.

Successful management of toxic epidermal necrolysis (TEN) with tumor necrosis factor-α inhibitors has been described in adults, but few cases have been reported in children. To date, only four pediatric cases of TEN treated with infliximab and one with etanercept have been published. We present the case of an 8-year-old boy diagnosed with TEN induced by levetiracetam, successfully treated with etanercept, systemic corticosteroids, and intravenous immunoglobulin.

Buschke-Ollendorff syndrome (BOS) is a rare autosomal dominant genodermatosis caused by heterozygous mutations in LEMD3 and characterized by connective tissue nevi and sclerotic bone lesions known as osteopoikilosis. We report a family with three individuals affected by BOS, two of whom manifested clinical and histopathological peculiarities, presenting with a depressed indurated plaque as the main cutaneous manifestation instead of the classic connective tissue nevi. Notable elastorrhexis was present in both biopsies.

Angiokeratoma circumscriptum is the rarest variant of angiokeratoma. It usually affects females and it is characterized by dark-red to blue-black confluent papules or nodules on lower limbs in a segmental and unilateral distribution. We describe the clinical and histopathological findings in a patient with angiokeratoma circumscriptum and discuss the etiology, associations, diagnosis, differential diagnosis, and treatment.

We have read with great interest Dr Recalcati’s review about skin manifestations in COVID‐19 as it is the first report on this subject1. In a recent review on clinical characteristics of coronavirus disease 2019 in China, rash was observed in 0,2% of cases2. However, from the trained eyes of a dermatologist, this percentage may be higher.

Aplasia cutis congenita (ACC) associated with fetus papyraceus is a rare subtype of aplasia cutis categorized as type V in Frieden's classification. It is characterized by stellate lesions in a symmetrical distribution over the trunk and proximal extremities. Conservative treatment is recommended, but there is not a well-defined therapeutic protocol. We report the case of a type V ACC in a preterm male newborn with lesions on the trunk and scalp successfully treated with topical 1% silver sulfadiazine and petrolatum gauze with an excellent evolution. This case associates a severe affectation of the scalp which represents a rare variant of type V ACC.

Keratoacanthoma centrifugum marginatum (KCM) is a rare variant of keratoacanthoma (KA), characterized by progressive peripheral growth, and usually devoid of deep invasion. Different systemic (oral retinoids) or topical treatments have been reported, but there is not a well-defined therapeutic protocol. We report the case of a KCM developing after photodynamic therapy (PDT) on the right leg of a 64-year-old woman. It was treated successfully with oral acitretin combined with topical 5-Fluorouracil + salicylic acid for 5 months. This is the first case of KCM developing after PDT and successfully treated with oral retinoid combined with topical treatment.